Elevated serum levels of soluble receptor activator of nuclear factors-κB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS)

Rheumatology

Volumn 45, Issue 10, 2006, Pages 1197-1200

  Kim, H R ^a   Kim, H Y ^b   Lee, Sang Heon ^a  

^a Konkuk University Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Ankylosing spondylitis; B ligand; Bone mineral density; Osteoporosis; Osteoprotegerin; Receptor activator of nuclear factors

Indexed keywords

C REACTIVE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADOLESCENT; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEMUR; FEMUR NECK; HUMAN; INFLAMMATION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIODIAGNOSIS; SACROILIITIS; SCORING SYSTEM; UPREGULATION;

ABSORPTIOMETRY, PHOTON; ACUTE DISEASE; ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BONE DENSITY; CASE-CONTROL STUDIES; DENSITOMETRY, X-RAY; FEMALE; FEMUR NECK; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33749598017     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel072     Document Type: Article

References (20)

1. Will R, Palmer R, Bhalla AK, Ring F, Calin A. Osteoporosis in early ankylosing spondylitis: A primary pathological event? Lancet 1989;2:1483-5.
2. Donnelly S, Doyle DV, Denton A, Rolfe I, McCloskey EV, Spector TD. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994;53:117-21.
3. El Maghraoui A, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol 1999;26:2205-9.
4. Crotti TN, Smith MD, Weedon H et al. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: Semiquantitative and quantitative analysis. Ann Rheum Dis 2002;61:1047-54.
5. Haynes DR, Barg E, Crotti TN et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. Rheumatology 2003;42:123-34.
6. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004;31:2236-41.
7. Grisar J, Bernecker PM, Aringer M et al. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002;29:1430-6.
8. Golmia RP, Sousa BD, Scheinberg MA. Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacos et al. Arthritis Rheum 2002;46:3390-1.
9. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
10. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
11. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
12. Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996; 35:66-71.
13. Wanders AJ, Landewe RB, Spoorenberg A et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? a comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum 2004;50:2622-32.
14. Cho ML, Yoon CH, Hwang SY et al. Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts. Arthritis Rheum 2004;50:776-84.
15. Trofimov S, Pantsulaia I, Kobyliansky E, Livshits G. Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/ macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol 2004;150:305-11.
16. Sivri A, Kilinc S, Gokce-Kutsal Y, Ariyurek M. Bone mineral density in ankylosing spondylitis. Clin Rheumatol 1996;15:51-4.
17. Capaci K, Hepguler S, Argin M, Tas I. Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 2003;44:379-84.
18. El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine 2004;71:291-5.
19. Meirelles ES, Borelli A, Camargo OP. Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol 1999;18:364-8.
20. Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52.